These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27341410)

  • 1. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
    Teagle AR; Gilbert DC; Jones JR; Burkill GJ; McKinna F; Dizdarevic S
    Nucl Med Commun; 2016 Oct; 37(10):1038-45. PubMed ID: 27341410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of
    Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
    J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of positron emission tomography-computed tomography in the management of anal cancer.
    Mistrangelo M; Pelosi E; Bellò M; Ricardi U; Milanesi E; Cassoni P; Baccega M; Filippini C; Racca P; Lesca A; Munoz FH; Fora G; Skanjeti A; Cravero F; Morino M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):66-72. PubMed ID: 22592047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma.
    Vercellino L; Montravers F; de Parades V; Huchet V; Kerrou K; Bauer P; Touboul E; Talbot JN
    Int J Colorectal Dis; 2011 Feb; 26(2):201-10. PubMed ID: 21061012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
    Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma.
    Goldman KE; White EC; Rao AR; Kaptein JS; Lien WW
    Pract Radiat Oncol; 2016; 6(5):e149-e154. PubMed ID: 26948134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
    Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
    Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET/CT in anal cancer - is it worth doing?
    Wells IT; Fox BM
    Clin Radiol; 2012 Jun; 67(6):535-40. PubMed ID: 22208962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer.
    Mistrangelo M; Pelosi E; Bellò M; Castellano I; Cassoni P; Ricardi U; Munoz F; Racca P; Contu V; Beltramo G; Morino M; Mussa A
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):73-8. PubMed ID: 19632066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can (18)F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer?
    Ul-Hassan F; Simo R; Guerrero-Urbano T; Oakley R; Jeannon JP; Cook GJ
    Clin Nucl Med; 2013 Apr; 38(4):263-5. PubMed ID: 23429398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/CT in the evaluation of anal carcinoma.
    Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
    Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
    Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the impact of FDG-PET in the management of anal cancer.
    Nguyen BT; Joon DL; Khoo V; Quong G; Chao M; Wada M; Joon ML; See A; Feigen M; Rykers K; Kai C; Zupan E; Scott A
    Radiother Oncol; 2008 Jun; 87(3):376-82. PubMed ID: 18453023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.
    Taghipour M; Sheikhbahaei S; Trahan TJ; Subramaniam RM
    Nucl Med Commun; 2016 Jun; 37(6):602-8. PubMed ID: 27110955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.